Lower Urinary Tract Infection Clinical Trial
Official title:
Randomised, Open-label, Controlled Clinical Trial to Evaluate the Efficacy of a Product Consisting of D Mannose 2 g+ Cran-max 500 mg+ Vitamin D3 0.001 mg (UROMANNOSA®) in Women With Recurrent Lower Urinary Tract Infections
To analyze the clinical impact of a food supplement composed of D Mannose, cranberry extract (Cran-max) and Vitamin D3 in the prevention of recurrent lower urinary tract infections (UTI)
Once patients have been informed about the study, the potential risks and treatment alternatives, those who meet the selection criteria, agree to participate and sign the informed consent, will be randomly and openly assigned, in a 1:1:1 ratio, to one of the following groups: Group A: Patients with repeat UTIs who will receive prophylactic treatment for 6 Months. Group B: Patients with repeat UTIs who will receive prophylactic treatment for 3 Months. Control group: Patients with recurrent UTIs who will not receive as prophylactic treatment the supplement under study. The three groups will be treated following standard clinical practice with follow-up at 3, 6, 9 and 12 months after inclusion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04140669 -
Automated Myocardial Performance Index Using Samsung HERA W10
|
||
| Completed |
NCT03729336 -
PEEZY Midstream Urine Device Compared to Catheterized Urine Sample
|
N/A |